VX5 is a humanized IgG1kappa monoclonal antibody inhibitor targeting BCA-1/CXCL13. It significantly inhibits human CXCL13-mediated CXCR5 internalization and blocks the CXCL13-dependent chemotaxis and migration of both human and mouse B cells (with EC50 values of 105 nM for human tonsil cells and 253 nM for pre-B-697-hCXCR5 cells). VX5 is applicable in the study of autoimmune diseases such as multiple sclerosis and arthritis, as well as cancers like gastric lymphoma and colon cancer.
Target-Kategorie:
CXCR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
